CHICAGO (GenomeWeb) – Newly launched cancer screening firm Thrive Earlier Detection is aiming to be among the first to bring genomic pan-cancer early detection tests to the clinic, confident that the relative simplicity and cost effectiveness of its approach — coupled with extremely high specificity — will ease a path to adoption.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.